NDA 021078 · Glaxosmithkline
Malarone Pediatric
Atovaquone, Proguanil Hydrochloride · Oral · Antimalarial; Antiprotozoal
Priority reviewLast checked: Nov 20, 2026Latest source record: Jun 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jul 14, 2000
Approved uses
3
Original approval plus efficacy supplements
Registered trials
57
5 Phase 3, 2 recruiting
FAERS reports
2,130
1,563 serious, 33 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 11, 2026.
Atovaquone and Proguanil Hydrochloride tablets are an antimalarial indicated for: • prophylaxis of Plasmodium falciparum (P. falciparum) malaria, including in areas where chloroquine resistance has been reported. ( 1.1 ) • treatment of acute, uncomplicated P. falciparum malaria. ( 1.2 ) 1.1 Prevention of Malaria Atovaquone and Proguanil Hydrochloride tablets are indicated for the prophylaxis of Plasmodium falciparum (P. falciparum) malaria, including in areas where chloroquine resistance has been reported. 1.2 Treatment of Malaria Atovaquone and Proguanil Hydrochloride tablets are indicated for the treatment of acute, uncomplicated P. falciparum malaria. Atovaquone and proguanil hydrochloride have been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance.
Mechanism: Atovaquone and Proguanil Hydrochloride tablets, a fixed-dose combination of atovaquone and proguanil hydrochloride, is an antimalarial agent [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 2, 2003 Supplement 6 · Efficacy · priority review LabelLetter
- Aug 2, 2002 Supplement 3 · Efficacy ReviewLabelLetter
- Jul 14, 2000 Original approval · Type 4 - New Combination · priority review LetterReviewLabel
2 products under this application
- MALARONE PEDIATRIC · ATOVAQUONE 62.5MG; PROGUANIL HYDROCHLORIDE 25MG · TABLET, ORAL · Prescription · TE AB
- MALARONE · ATOVAQUONE 250MG; PROGUANIL HYDROCHLORIDE 100MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Atovaquone" as an intervention, any sponsor and status, largest first.
- A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or SulfonamidesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000802 · 700 participants
Drug: Atovaquone; Dapsone · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 44 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000811 · 690 participants
Drug: Azithromycin; Atovaquone and 1 more · For: Bacterial Infections; Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Birmingham, Alabama; Mobile, Alabama; La Jolla, California · 75 sites in all
- Chloroquine Alone or in Combination for Malaria in Children in MalawiPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00379821 · 640 participants · Start Feb 2007 · Primary completion Aug 2009
Drug: Atovaquone-proguanil; Artesunate and 2 more · For: Plasmodium Falciparum Infection
Sites: Blantyre, Malawi
- A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMXPivotal-lookingCompleted
Glaxo WellcomeGSK (GSK)
NCT00002340 · 615 participants
Drug: Atovaquone; Pentamidine isethionate · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Maitland, Florida; Tampa, Florida; New York, New York · 5 sites in all
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
- Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)Pivotal-lookingNot yet recruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT07357103 · 416 participants (planned) · Start Mar 2026 · Primary completion Mar 2029
Drug: Clindamycin + primaquine; Pentamidine and 1 more · For: Pneumocystis; Pneumocystis Infection; Pneumocystis Carinii Infection and 5 more
- Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated MalariaPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01150344 · 317 participants · Start Jul 2010 · Primary completion Apr 2014
Drug: Malarone (atovaquone + proguanil combination); RIAMET (artemether + LUMEFANTRIN combination) · For: Malaria
Sites: Bobigny, France
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000655 · 300 participants · Primary completion Jan 1992
Drug: Atovaquone; Sulfamethoxazole-Trimethoprim · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Birmingham, Alabama; Harbor City, California; Los Angeles, California · 38 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea193
- diarrhoea170
- vomiting153
- pyrexia150
- headache132
- malaria123
- drug ineffective122
- dizziness112
- fatigue108
- malaise102
- rash82
- hallucination76
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 121 |
| 2005 | 169 |
| 2006 | 160 |
| 2007 | 192 |
| 2008 | 162 |
| 2009 | 133 |
| 2010 | 106 |
| 2011 | 131 |
| 2012 | 111 |
| 2013 | 103 |
| 2014 | 88 |
| 2015 | 80 |
| 2016 | 89 |
| 2017 | 73 |
| 2018 | 83 |
| 2019 | 75 |
| 2020 | 37 |
| 2021 | 20 |
| 2022 | 49 |
| 2023 | 33 |
| 2024 | 46 |
| 2025 | 39 |
| 2026 | 30 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Malarone (Atovaquone/Proguanil HCl)
2024 spending
$3K
Beneficiaries
23
24 claims
Per beneficiary
$142
$5.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $3,317 |
| 2023 | $3,409 |
| 2024 | $3,260 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C, Katergi K, Sorin M, et al. · Clin Microbiol Infect 2024 · Systematic Review, Comparative Study
- Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Hatzl S, Posch F, Scholz L, et al. · Clin Microbiol Infect 2025 · Systematic Review, Comparative Study
- A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria.
Nakato H, Vivancos R, Hunter PR · J Antimicrob Chemother 2007 · Meta-Analysis, Systematic Review
- Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.
Staines HM, Burrow R, Teo BH, et al. · J Antimicrob Chemother 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Mefloquine for preventing malaria during travel to endemic areas.
Tickell-Painter M, Maayan N, Saunders R, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
Rakedzon S, Neuberger A, Domb AJ, et al. · J Travel Med 2021 · Systematic Review
Sponsor: GSK · Also marketed as Malarone
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.